Testimony & Comments

PAL and our coalition members often submit testimony and comments to federal agencies on a variety of issues related to the pricing and marketing of prescription drugs. Below are copies of some of the recent comments we have submitted. 

• Comments of PAL, The Prescription Project, National Physicians Alliance and US PIRG on FDA's Draft Guidance for Industry: Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices (April 21, 2008)  
  
  
• Comments of PAL & 26 other organizations to FDA on proposed study of drug advertisements (October, 2007)
  
  
• Comments to Federal Trade Commission on AUthorized Generics Study
  (June, 2006)
  
  
• Comments of PAL & 23 other orgnaizations to FDA on proposed study of prescription drug coupons, calling for ban on such coupons
  (April 2006)
  
  
• Testimony of PAL at FDA hearing on Direct-to-Consumer Advertising of Prescription Drugs
  (November 2005)